Oncotelic Launches PR Chatbot
June 12, 2023 08:10 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), annouces the beta unveiling of a pioneering press...
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™
February 16, 2021 09:52 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
MATEON TO HOST VIRTUAL SYMPOSIUM ADDRESSING COVID-19 ON NOVEMBER 11, 2020
November 02, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
“Advancing Ayurveda Through Ethnobiology Drug Development”Topics Include Mateon’s ARTIShield™ for the Treatment of COVID-19 and COVID-19/Influenza Coinfection AGOURA HILLS, Calif., Nov. 02, 2020 ...
MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
October 07, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β...
MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.
September 14, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its...